Reuters logo
10 months ago
BRIEF-Chemocentryx says its CCR2 inhibitor CCX872 shown to reduce liver fibrosis in nash models
October 18, 2016 / 2:37 PM / 10 months ago

BRIEF-Chemocentryx says its CCR2 inhibitor CCX872 shown to reduce liver fibrosis in nash models

Oct 18 (Reuters) - Chemocentryx Inc

* chemocentryx's ccr2 inhibitor ccx872 shown to reduce liver fibrosis in nash models

* Chemocentryx inc - third-generation ccr2 inhibitor, ccx598, is poised to enter investigational new drug enabling studies in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below